Compare CAPR & ECO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAPR | ECO |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | Greece |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | N/A |
| Metric | CAPR | ECO |
|---|---|---|
| Price | $22.51 | $42.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $41.38 | $37.00 |
| AVG Volume (30 Days) | ★ 1.0M | 413.4K |
| Earning Date | 03-18-2026 | 02-18-2026 |
| Dividend Yield | N/A | ★ 4.93% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.38 |
| Revenue | $11,130,509.00 | ★ $349,886,578.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17,308.50 | $5.10 |
| P/E Ratio | ★ N/A | $21.46 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.30 | $17.91 |
| 52 Week High | $40.37 | $43.22 |
| Indicator | CAPR | ECO |
|---|---|---|
| Relative Strength Index (RSI) | 49.65 | 62.99 |
| Support Level | $23.23 | $41.14 |
| Resistance Level | $25.45 | $43.22 |
| Average True Range (ATR) | 1.39 | 1.20 |
| MACD | -0.01 | 0.09 |
| Stochastic Oscillator | 64.01 | 73.45 |
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Okeanis Eco Tankers Corp owns and operates tanker vessels in Greece. The business of the company is to own, charter out, and operate tanker vessels. The company owns, through its vessel-owning subsidiaries, a fleet of around seven tanker vessels and has around eight tanker vessels on order. The sailing fleet consists of around six modern Suezmax tankers and eight VLCC tankers.